Alcoholic hepatitis: Yes to prednisolone and no to pentoxifylline [version 1; referees: not peer reviewed] by Davies, O & Dezfulian, C
F1000Research
Not Peer Reviewed
This article is an F1000 Faculty Critique and
has not been subject to external peer review.
Discuss this article
 (0)Comments
F1000 FACULTY CRITIQUE
 Alcoholic hepatitis: Yes to prednisolone and no to pentoxifylline
[version 1; referees: not peer reviewed]
Oluwaseun Davies, Cameron Dezfulian
Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, 15261, USA
Abstract
An evaluation of a recent study by Thursz MR, Richardson P, Allison M . “et al
”. N Engl J MedPrednisolone or Pentoxifylline for Alcoholic Hepatitis
2015;372:1619-28. PubMed PMID: 25901427. EudraCT number,
2009-013897-42. Current Controlled Trials number ISRCTN88782125.
 This article is included in the  channel.Critical care
 Cameron Dezfulian ( )Corresponding author: dezfulianc@upmc.edu
 Davies O and Dezfulian C. How to cite this article: Alcoholic hepatitis: Yes to prednisolone and no to pentoxifylline [version 1; referees:
  2016, :395 (doi: )not peer reviewed] F1000Research 5 10.12688/f1000research.8336.1
 © 2016 Davies O and Dezfulian C. This is an open access article distributed under the terms of the Copyright: Creative Commons Attribution
, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Licence
 The author(s) declared that no grants were involved in supporting this work.Grant information:
 Competing interests: The authors declare that they have no competing interests.
 24 Mar 2016, :395 (doi: ) First published: 5 10.12688/f1000research.8336.1
 24 Mar 2016, :395 (doi: )First published: 5 10.12688/f1000research.8336.1
 24 Mar 2016, :395 (doi: )Latest published: 5 10.12688/f1000research.8336.1
v1
Page 1 of 4
F1000Research 2016, 5:395 Last updated: 24 MAR 2016
Critique of:
Citation
Thursz MR, Richardson P, Allison M, Austin A, Bowers M, 
Day CP, Downs N, Gleeson D, MacGilchrist A, Grant A, Hood S, 
Masson S, McCune A, Mellor J, O’Grady J, Patch D, Ratcliffe 
I, Roderick P, Stanton L, Vergis N, Wright M, Ryder S, Forrest 
EH; STOPAH Trial. “Prednisolone or Pentoxifylline for Alco-
holic Hepatitis”. N Engl J Med 2015;372(17):1619–28. PubMed 
PMID: 25901427. EudraCT number: 2009-013897-42. Current 
Controlled Trials number: ISRCTN88782125.
Background
Alcoholic hepatitis is a clinical syndrome characterized by jaundice 
and liver impairment that occurs in patients with a history of heavy 
and prolonged alcohol use. The short-term mortality among patients 
with severe disease exceeds 30%. Prednisolone and pentoxifyl-
line are both recommended for the treatment of severe alcoholic 
hepatitis, but uncertainty about their benefit persists.
Objective
To determine whether corticosteroids or pentoxifylline reduce the 
mortality associated with severe alcoholic hepatitis at 28 days, 
90 days and 1 year.
Design
Multicenter, double-blind, randomized trial with a 2-by-2 factorial.
Setting
Patients were recruited from January 2011 through February 2014 
at 65 hospitals across the United Kingdom.
Subjects
All patients admitted with suspected severe alcoholic hepatitis were 
evaluated for eligibility. A clinical diagnosis that was based on a 
history of recent excess alcohol consumption and the absence of 
other causes of liver disease was used for trial recruitment.
Intervention
Patients were randomly assigned to one of four groups: 1) a group 
that received a double placebo, 2) a group that received active 
prednisolone and a pentoxifylline-matched placebo, 3) a group 
that received active pentoxifylline and a prednisolone-matched 
placebo, or 4) a group that received both active prednisolone and 
pentoxifylline.
Outcomes and follow up
1 year follow up with primary outcome of 28-day mortality and 
secondary outcomes of liver transplantation or mortality at 90 days 
and 1 year.
Results
A total of 1103 patients underwent randomization, and data from 
1053 were available for the primary end-point analysis (28-day 
mortality). Mortality at 28 days was 17% (45 of 269 patients) 
in the placebo–placebo group, 14% (38 of 266 patients) in the 
prednisolone–placebo group, 19% (50 of 258 patients) in the 
pentoxifylline–placebo group, and 13% (35 of 260 patients) in 
the prednisolone–pentoxifylline group. The odds ratio for 28-day 
mortality with pentoxifylline was 1.07 (95% confidence inter-
val [CI], 0.77 to 1.49; P=0.69), and that with prednisolone was 
0.72 (95% CI, 0.52 to 1.01; P=0.06). Combined pentoxyfylline- 
prednisolone therapy did not improve 28-day mortality. At 
90 days and at 1 year, there were no significant between-group 
differences. Serious infections occurred in 13% of the patients 
treated with prednisolone versus 7% of those who did not (P=0.002). 
In a prespecified secondary analysis, in which a multivariate 
backward stepwise (not prespecified) logistic-regression was used 
to adjust for variables associated with prognosis in univariate anal-
ysis, the odds ratio for 28-day mortality among the patients who 
received prednisolone, as compared with those who did not, was 
0.61 (95% CI, 0.41 to 0.91; P=0.02). However, the effect of pred-
nisolone on mortality at 90 days (odds ratio, 1.00; 95% CI, 0.73 to 
1.36; P=0.98) and at 1 year (odds ratio, 1.01; 95% CI, 0.74 to 1.39; 
P=0.94) was not significant.
Conclusions
Pentoxifylline did not improve survival in patients with alcoholic 
hepatitis. Prednisolone was associated with a reduction in 28-day 
mortality that did not reach significance and with no improve-
ment in outcomes at 90 days or 1 year. (Funded by the National 
Institute for Health Research Health Technology Assessment 
program; STOPAH EudraCT number, 2009-013897-42, and 
Current Controlled Trials number, ISRCTN88782125.)
Abstract adapted from the original provided courtesy of PubMed: 
A service of the National Library of Medicine and the National 
Institutes of Health. 
Commentary
Despite decades of research on its management, alcoholic hepatitis 
(AH) remained a significant cause of morbidity and mortality; 
Twenty eight day mortality rates were as high as 35% for individu-
als with a Maddrey’s Discriminant Function (MDF) score of at 
least 321. In 2008 A Cochrane meta-analysis of RCTs comparing 
glucorticoid therapy to placebo or no intervention, was published2. 
A total of only 721 patients were included. The results showed that 
glucorticoids did not reduce mortality compared to placebo but 
in a subgroup analysis done for patients with MDF of at least 32 
there was a significant mortality reduction. The included studies 
were mostly very small and there was a risk for bias in 12 of 15. 
In 2011, another meta-analysis was published that combined the 
results of only the most recent RCTs on glucorticoids vs other ther-
apy in patients with MDF greater than 323. A total of 418 patients 
were enrolled and the results showed a survival benefit for ster-
oid use: 28-day mortality rate of ~20% in the steroid group com-
pared to ~35% in the placebo or other therapy group, p=0.0005. 
Pentoxifylline has been less well studied than glucorticoids in AH. 
The key study that showed a significant benefit for pentoxifyl-
line was published in 2000 by Akriviadis et al.4. It was a double 
blind randomized trial enrolling 101 patients that showed a 24.5% 
in-hospital mortality rate in the pentoxifylline group as compared 
to a 46% mortality rate in the placebo group resulting in a rela-
tive risk of 0.59 for death (p = 0.037). However in 2009, Cochrane 
published a meta-analysis of 5 RCTS with a total of 336 patients5. 
This showed that pentoxifylline reduced mortality compared with 
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control (RR 0.64; 95% CI 0.46 to 0.89). However, this result 
was not supported by trial sequential analysis, which adjusts for 
multiple testing on accumulating data. Of the five included trials, 
four (80%) had a high risk of bias. As a result of the poor quality 
of most of the studies, the authors concluded that no conclusions 
could be drawn regarding whether pentoxifylline had a positive, 
negative, or neutral effect on participants with alcoholic hepati-
tis. Mathurin et al.6 found no evidence of an additive effect when 
pentoxifylline was added to prednisolone confirming the findings 
of the COPE trial7. Based on these published randomized control-
led trials (RCT) and meta-analyses, prednisolone and pentoxifyl-
line were incorporated in the past 5 years into guidelines of the 
American Association for the Study of Liver Disease (AASLD) and 
the European Association for the Study of the Liver (EASL)8,9 but 
these recommendations remained controversial due to the quality of 
the data upon which they were based. 
The STOPAH trial had 90% power to detect a reduction in 28-day 
mortality from 30% to 21% based on its sample size of 1026 
patients. Analyses were on an intention-to-treat basis. Logistic 
regression was used to compare 28-day, 90-day and 1 year mor-
tality, and liver transplantation rates after adjustments for risk 
category. Cox proportional-hazards regression was used to 
compare 1-year survival among the groups, and Kaplan–Meier 
curves for 1-year survival were plotted. All P values were two-
sided. As part of a pre-specified analysis, individual and treatment 
variables that were found to be significant in univariate analyses 
were used in multivariate logistic-regression analysis, and back-
ward elimination (which was not prespecified) was applied at a 
5% significance level. From Jan 2011, for 3yrs, 5234 potential 
patients were screened and 4131 were excluded after the various 
eligibility criteria were applied. 1103 patients were randomized for 
the trial in nearly even groups. The four groups had similar baseline 
characteristics and laboratory values.
In unadjusted analysis, prednisolone showed a strong trend towards 
reduced 28 day mortality (P=0.06) whereas pentoxifylline did not 
(P=0.69). Neither drug influenced mortality, or the need for liver 
transplantation at 90 days or 1 year - though one could argue that 
long term improvement in outcomes for AH is mostly determined 
by alcohol cessation not the acute treatment of the hepatitis. The 
dramatic increase in mortality or transplantation from 16% 
(28 days) to 29% (90 days) to 56% (1 year) underscores the 
chronic severity of this condition and argues against the meaning-
fulness of longer term outcomes without alcohol cessation. There 
was no significant interaction between prednisolone and pentoxi-
fylline (P=0.41). In a secondary analysis that adjusted prognosti-
cally important variables, prednisolone improved 28-day mortality 
(OR = 0.61, p = 0.02) but not 90 day or 1 year outcomes. Infec-
tion was higher in the prednisolone group but mortality from infec-
tion was similar across groups. Thus the study supports a short term 
benefit of prednisolone in AH but no benefit from pentoxifylline 
or the combination.
The study had a number of strengths. Firstly, it had a wide 
catchment area cutting across 65 hospitals in the UK and increas-
ing the generalizability of the results. Secondly, the use of a 2×2 
factorial design was appropriate and well executed. It allowed for 
the concomitant testing of more than one hypothesis in an efficient 
manner, whilst monitoring for possible interaction effects. Thirdly, 
it appropriately adjusted for important prognostic variables such 
as age, encephalopathy, WBC count, PT, Bilirubin, creatinine and 
urea levels. An adjusted analysis protects against chance imbal-
ance that can occur in a randomized controlled trial, particularly 
in smaller trials such as these. In addition, they had pre-specified 
which variables would be examined for inclusion in this analysis, 
which reduces bias and makes it more reliable. It was also probably 
reasonable to use backward stepwise regression as it allowed for the 
fine-tuning of prior selected variables to get the variables that were 
of most statistical significance.
The study had a number of limitations. Self-reported alcohol 
consumption was used for inclusion which unfortunately is not 
reliable, particularly amongst heavy drinkers10 associated with 
severe AH. Although it is difficult to envision a more accurate 
method and the use of biopsy criteria would violate the usual 
standard of care. No data were reported on resultant morbidity and 
quality of life measures which are important patient centered out-
comes. The lower than expected placebo/placebo mortality rate 
could have resulted in an underpowering hence the trend in the 
prednisolone effect though the pentoxifylline effect was certainly nil.
The STOPAH study is the most comprehensive study to date, 
looking at the effectiveness of prednisolone and pentoxifylline in 
treating severe alcoholic hepatitis. When these results are taken in 
context of the prior studies, there is definitely a suggestion of ben-
efit with steroid therapy. This benefit comes at the cost of more 
infections. Like many diseases, mortality due to AH has stead-
ily decreased making sample size calculations challenging, and 
resulting in, an inadvertently underpowered study.
Recommendation
Prednisolone in addition to supportive modalities should be the 
main stay of therapy for patients with severe AH whereas pentoxi-
fylline has no role in this disease. We should not lose sight of the 
fact that at 1yr, over 50% of the patients had either died or received 
liver transplantation underscoring the need to pursue sustained 
alcohol abstinence as the key for improved medium to long term 
survival.
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